Medinol, Cordis in stent distribution pact:
This article was originally published in Clinica
Israeli stent specialist Medinol has signed a definitive distribution agreement with Johnson & Johnson's interventional vascular technology arm Cordis, for the exclusive global rights to its line of bare metal stents. The companies will work towards filing the initial applications to market the products globally in the second half of 2007, except in the US, where this is expected to take place in the first half of 2008. Cordis, of Miami Lakes, Florida, will acquire the Tel Aviv manufacturer's stainless steel and cobalt chromium stents, designed to provide deliverability, conformability and scaffolding qualities to physicians.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.